Global Community

Key Investment Theses: TAV Airports Holding is approaching the end of one of the most intensive investment cycles in its history by 2025. This period of massive capital expenditure (CapEx), totaling over €2.5 billion, including capacity expansion at Antalya Airport, a new terminal building at Almaty Airport, and concession renewal investments at Ankara Esenboğa, has transformed the company into an asset platform that will generate cash for decades to come.Read more

The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons: * Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we've seen in the recent price dips.Read more

Sirios and OVI combined to form a single, Osisko-backed company which now owns a portfolio of properties near James Bay, Quebec. Of primary importance is their flagship project: Cheechoo.Read more

🪥Business Overview Key Metrics Total: 9.5/17 +2 ✅ Projected Operating Margin: 25.16% +0 ⚠️ Projected 5-Year Revenue CAGR: 3.71% +1 ✅ Last 5-Year ROIC: 17.20% +1 ✅ Estimated Cost of Capital: 8.32% (less than ROIC) +1 ✅ Last 5-Year Shares Outstanding CAGR: -1.47% -1 ❌ Projected 5-Year EPS CAGR: 4.69% (given the ease of manipulating earnings metrics, sub-10% growth warrants caution) +0 ⚠️ Projected 5-Year Dividend CAGR: 4.73% +1.5 ✅ Moody's Rating: Aa3 +2 ✅✅ Morningstar Moat: Wide +2 ✅✅ Morningstar Uncertainty: Low Procter & Gamble despite being within a very competitive industry still has some competitive advantages shown on its higher operating margin above the ~20% mark and the Morning Star Wide Moat. Also the fact that the ROIC is double the Cost of Capital means its capital allocation is being well managed.Read more

Lexaria Bioscience is testing multiple drug agents using their DehydraTECH (DHT) technology for oral and topical delivery of medications such as GLP-1and CBD. The DehydraTECH is showing substantial improvement in bioabsorption, brain permeation, taste maksing, and side effect reduction.Read more

1. The Narrative: Transitioning from Old Cash to Digital Infrastructure The Cash Fortress: In a world trending toward digital, physical cash is not disappearing, it is concentrating!Read more

⚖️ Business Overview Key Metrics Total: 9/17 +2 ✅ Projected Operating Margin: 26.38% +0 ⚠️ Projected 5-Year Revenue CAGR: 6.69% +1 ✅ Last 5-Year ROIC: 16.60% +1 ✅ Estimated Cost of Capital: 6.94% (less than ROIC) +1 ✅ Last 5-Year Shares Outstanding CAGR: -2.77% -1 ❌ Projected 5-Year EPS CAGR: 9.49% (given the ease of manipulating earnings metrics, sub-10% growth warrants caution) +0 ⚠️ Projected 5-Year Dividend CAGR: 7.44% +1 ✅ Moody's Rating: A3 +2 ✅✅ Morningstar Moat: Wide +2 ✅✅ Morningstar Uncertainty: Low Wolters Kluwer demonstrates strong operating margins of 26%, evidencing both competitive advantages and pricing power. This operational strength aligns with Morningstar's Wide Moat rating and notably rare Low Uncertainty designation—signaling a stable, well-entrenched industry position.Read more

Key Investment Arguments: Excessively Discounted Asset Value: RGYAS shares are currently trading at approximately a 55% discount to their Net Asset Value (NAV) at the current market price. Considering the company's "Best in Class" (B) shopping mall portfolio and successful debt reduction operations, this indicates an overly pessimistic market pricing.Read more

The Game-Changing Executive Order: A $11.4B Company's Perfect Storm Sometimes the stars align in ways that even the most astute investors couldn't predict. For IREN Limited (NASDAQ: IREN), currently valued at $11.4 billion with shares trading around $42 , the Trump Administration's July 23rd Executive Order on data centre permitting represents exactly that kind of celestial convergence.Read more